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Abstract
The exogenous anabolic-androgenic steroid (AAS) stanozolol stays one of the most
detected substances in professional sports. Its detection is a fundamental part of
doping analysis, and the analysis of this steroid has been intensively investigated for
a long time. This contribution to the detection of stanozolol doping describes for the
first time the unambiguous proof for the existence of 17-epistanozolol-10N-
glucuronide and 17-epistanozolol-20N-glucuronide in stanozolol-positive human
urine samples due to the access to high-quality reference standards. Examination of
excretion study samples shows large detection windows for the phase-II metabolites
stanozolol-10N-glucuronide and 17-epistanozolol-10N-glucuronide up to 12 days and
respectively up to almost 28 days. In addition, we present appropriate validation
parameters for the analysis of these metabolites using a fully automatic method
online solid-phase extraction (SPE) method already published before. Limits of identi-
fication (LOIs) as low as 100 pg/ml and other validation parameters like accuracy,
precision, sensitivity, robustness, and linearity are given.
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1 | INTRODUCTION
The family of anabolic-androgenic steroids (AAS) belongs to one of
the most common illicitly used substance class in the world of profes-
sional sports. Within this large group of different drugs, the synthetic
steroid stanozolol (17α-methyl-5α-androst-2-eno[3,2-c]pyrazol-17β-
ol) attributes to the highest number of positive cases according to
World Anti-Doping Agencies (WADA) statistics.1,2 This exogenous
steroid is well known analytically and various strategies for its detec-
tion are described in the literature. Because this steroid was synthe-
sized in the late 1950s, there was plenty of time to develop many
different approaches to analyze stanozolol and its metabolites.3 In
1986, the team around Donike and Schänzer developed the first
method for the analysis of the metabolite 30-OH-stanozolol applying
gas chromatography–mass spectrometry (GC–MS).4 In the following
35 years, many other techniques, primarily based on mass spectro-
metric techniques coupled to on either gas (GC–MS) or liquid chroma-
tography (LC–MS), for analyzing a large number of different
stanozolol metabolites, were published.5–20
In general, the traditional approach for the simultaneous analysis
of several different steroids is to perform enzymatic hydrolysis to
cleave highly polar phase-II conjugates, like glucuronic acids and
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sulfates, followed by liquid–liquid extraction and the analysis of
remaining phase-I metabolites and parent molecules with GC– or
LC–MS.21,22 For the measurement with GC–MS, the analytes are addi-
tionally derivatized with N-methyl-N-trimethylsilyltrifluoroacetamide
(MSTFA) to reduce their polarity. This kind of approach is the gold
standard nowadays and is commonly performed by anti-doping labora-
tories worldwide for the routine initial testing procedure (ITP), often
including the detection of stanozolol parent or phase-I metabolites.
However, with the emergence of more powerful LC–MS devices,
a new, modern way of steroid analysis was developed. With this
approach, time- and resource-consuming steps of enzymatic hydroly-
sis, extraction and derivatization are omitted. Phase-II conjugates of
steroids are analyzed directly without further extraction or concentra-
tion steps.15–20,23–29 In 2015, the team around G. Balcells already pro-
posed the analysis of a high number of relevant phase-II metabolites
for anti-doping screening purposes.16 Nowadays, high-resolution
(HR) LC–MS devices are frequently used in order to increase sensitiv-
ity and selectivity of the measurement. In 2013, Van Eenoo et al.
showed the promising potential of this approach for the detection of
stanozolol abuse for the first time.17 The team developed an approach
for the direct analysis of 30-OH-stanozolol glucuronide in human
urine.
This idea was adopted by developing a simple but powerful
method for the detection of phase-II metabolites of steroids, as previ-
ously published. This approach was optimized by placing a fully auto-
mated online solid-phase extraction (SPE) procedure upstream of the
analytical measurement with LC-HRMS.18 Next to the aspect of
saving time and resources by direct analysis of phase-II conjugates, no
enzymatic hydrolysis step using, for example, β-glucuronidase from
Escherichia coli is required. Consequently, issues like incomplete or
inhibited hydrolysis to yield phase-I metabolites, as necessary for GC–
MS methods, are no longer relevant. Literature and own experience
demonstrates that, for example, stanozolol-N-glucuronides are hardly
hydrolyzed with enzymes commonly used in anti-doping laborato-
ries.19 As a consequence, these metabolites are usually not detected
in routine ITP at all.
We have observed that the excretion profile for stanozolol-N-
glucuronides is consistent in most positive samples, depending on the
drug's application time. Figure 1 shows a typical extracted ion chro-
matogram (XIC, m/z = 505.3 à 329.3) for stanozolol-mono-
glucuronides of a positive urine sample and the known corresponding
metabolite structures, which are based on the metabolically
unchanged molecule of stanozolol.
The structures behind Peaks A–C were already suggested by
Schänzer et al. in 2013 and Thevis et al. in 2015.19,20 Peak A repre-
sents stanozolol-170O-glucuronide, and Peaks B and C represent two
N-glucuronides of stanozolol. These two metabolites were identified
and characterized in our previous work.18 These two phase-II metabo-
lites were identified as stanozolol-10N- (B) and stanozolol-20N-
glucuronide (C). Aim of the present study was to use this method for
characterization of the two remaining metabolites D and E. Schänzer
and Thevis already suggested the appearance of a 17-epistanozolol-
glucuronide in above-mentioned studies. However, in both cases, an
unambiguous identification was not successful due to the lack of
F IGURE 1 Extracted ion chromatogram (XIC) (m/z = 505.3 à 329.3) of stanozolol-mono-glucuronides and corresponding chemical
structures: (a) stanozolol-170O-glucuronide, (b) stanozolol-10N-glucuronide, (c) stanozolol-20N-glucuronide, (d) 17-epistanozolol-10N-glucuronide,
and (e) 17-epistanozolol-20N-glucuronide (see text below)
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high-quality reference material. Furthermore, differentiation of
17-epistanozolol-10N- and 17-epistanozolol-20N-glucuronide metabo-
lites was not performed. The structures of these two new metabolites
and the parent molecule are shown in Figure 2.
At the Institute of Applied Synthetic Chemistry, Technical Univer-
sity of Vienna, Austria, these two metabolites were synthesized in an
amount suitable to confirm their structures with nuclear magnetic res-
onance (NMR) spectrometry. The detailed description of the synthesis
procedure and NMR analysis is still in progress and will soon be publi-
shed elsewhere. Unambiguous identification and characterization of
17-epistanozolol-10N- (II) and 17-epistanozolol-20N-glucuronide (III) is
given by using mass spectrometric techniques to compare these refer-
ence standards with stanozolol positive human urine samples from
excretion experiments or actual athletes. Additionally to the charac-
terization of these two new metabolites, the potential of all four N-
associated metabolites for a routine anti-doping analysis of stanozolol
is demonstrated. A comprehensive validation and the application of
the validated method to an excretion study for stanozolol demon-
strates the fitness for purpose of this analytical method as well as the
window of detection for stanozolol abuse.
2 | EXPERIMENT
2.1 | Chemicals, reagents, and solutions
Water (high-performance liquid chromatography, HPLC grade) and
Methanol (MeOH, HPLC grade) used for HPLC analysis were bought
from Biosolve Chimie (Dieuze, France). Formic acid (FA) used for
HPLC was purchased from Merck (Darmstadt, Germany). Water
(MQ) used for sample dilution was provided by a Milli-Q
water purification system (Millipore, Reference A+, Burlington,
Massachusetts, USA). Methanol used to prepare standard solutions
was supplied by Chem-Lab (Zedelgem, Belgium). The 16,16,17α-
d3-testosterone-glucuronide used as the internal standard (IS) was
bought from the National Measurement Institute Australia (Sydney,
Australia). All stanozolol metabolite standards were synthesized by
the team of Peter Gärtner at the Technical University of Vienna and
characterized by NMR spectroscopy. Chemical structures are shown
in Figure 2.
Stock solutions with a concentration of 1 μg/ml for IS and
standard substances were prepared by dissolving 1 μg of standard
substance in 1-ml MeOH. Standard working solutions were prepared
by diluting stock solutions with MeOH. Until use, solutions were
stored at 20C. Reference samples were prepared by adding work-
ing solutions directly to blank urine.
2.2 | Urine samples
According to WADA's collection guidelines, all positive urine
samples used in this project were collected by accredited sample
collection authorities.30 The samples have previously been analyzed
by the accredited anti-doping laboratory Seibersdorf Labor GmbH.
All samples are unanimously confirmed positive for stanozolol. The
samples were subsequently anonymized and approved for research.
Previously, the athletes gave permission to use the urine samples
for research purposes, according to the International Standard for
Laboratories (ISL).31 Samples used for the excretion study were pro-
vided by the accredited anti-doping laboratory Cologne, Institute of
Biochemistry—German Sport University Cologne, Germany. For
these samples, a male healthy volunteer received a single oral dose
of 5 mg of stanozolol (Winstrol®). Urine samples were then
collected up to 28 days after administration of the substance. A
written agreement was received from the participant and the
project was accepted by the local ethical committee.19 The
anonymized blank urine samples were provided from healthy female
and male volunteers. Until analysis, all urine samples were stored
at 20C.
2.3 | Sample preparation
For sample preparation, 250 μl of urine was diluted with 250 μl of
MQ, 15 μl of IS (30 ng/ml) solution was added, followed by vortexing
samples for 10 s.
F IGURE 2 Chemical structures of I: Stanozolol, II: 17-epistanozolol-10N-glucuronide, and III: 17-epistanozolol-20N-glucuronide
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2.4 | Online SPE coupled to liquid chromatography
HR mass spectrometry (online-SPE-LC-HRMS)
An online-SPE-LC-HRMS approach was chosen as analytical method.
The method is described in detail in a previous publication.18 Analytes
extraction is carried out fully automatically upstream the injection into
the Vanquish Horizon UHPLC+ system (Thermo Fisher, Austin, Texas,
USA). An Accucore Phenyl-Hexyl, 10  3-mm column with 2.6-μm
particle and 80-Å pore size (Fischer Scientific, Loughborough, UK) was
used as extraction column. As analytical column, a Kinetex EVO C-18,
100  2.1-mm column with 2.6-μm particle- and 100-Å pore size
(Phenomenex, Aschaffenburg, Germany) was applied. For chromatog-
raphy, mobile phases containing water with 0.2% v/v FA (Solvent A)
and methanol with 0.1% v/v FA (Solvent B), constant flow of
0.4 ml/min, constant temperature at 25C, and an injection volume of
25 μl were used. Following gradient was carried out: 10% Solvent B
for 2 min to load and wash the pre-column, 10% Solvent B up to
100% over 7 minutes, hold 100% B for 2 min and again 10% B for
2 min to flush and re-equilibrate the system.
HR mass spectrometric measurements were carried out on a
Q-Exactive Orbitrap system (Thermo Fisher, Austin, Texas, USA) in
positive electrospray ionization mode (ESI+) using the following
settings: spray voltage was set to 3.8 kV, and capillary temperature
was 320C. Nitrogen was used as sheath gas (pressure 25 units) and
as auxiliary gas (pressure 8 units, temperature 310C). Sweep gas flow
rate was set to 0 and s-lens radio frequency (RF) level was 55. A mass
resolution of 70,000 at m/z 200 and automatic gain control (AGC) to
2  105 ions were carried out.
Parallel reaction monitoring (PRM) was chosen as measuring
method. To extract ion chromatograms (XIC), transitions shown in
Table 1 with an ion extraction range of 5 ppm were used. Isolation
windows were set to ±1 m/z. Collision energies (CEs) were optimized
by injection of methanolic working solutions of reference substances.
Diagnostic ions and corresponding CEs are also shown in Table 1. The
software Thermo Xcalibur Qual Browser 4.1.45 was used for data
procession and calculation of monoisotopic masses. All systems were
supervised with Xcalibur 4.0 (Thermo Fischer).
2.5 | Method validation
Method validation parameters for qualitative and semi-quantitative
purposes were used according to the ISL. The following parameters
were acquired: specificity, precision, robustness, linearity, accuracy,
matrix effects, carryover and limit of identification (LOI). Detailed
descriptions of all parameters are given below. Method validation was
carried out by using the above described PRM method. Peak areas
gained from product ion 1 were used for all semi-quantitative parame-
ters. Concentrations were corrected with the IS and calculated with an
internal calibration curve measured in each sequence. Data processing
used the software Thermo Xcalibur Quan Browser 4.1.45 and parame-
ters were calculated with Microsoft Excel 2010. The minimum required
performance level (MRPL) for free stanozolol is 2 ng/ml, as defined in
the WADA Technical Document TD2019MRPL.32 Therefore, 50% of
MRPL, 1 ng/ml, were used for most validation parameters. According
to the WADA identification criteria, comparison of retention times and
ratios of relative abundances of two ion transitions were used to evalu-
ate the specificity, robustness and LOI.33 For comparisons, matrix-free
(MQ) samples were spiked with reference substances at the respective
concentrations.
2.6 | Specificity
Five different female and five different male blank urine samples from
healthy volunteers were analyzed (n = 10). Furthermore, a second set
of these 10 samples were spiked with 1-ng/ml standard working solu-
tion. Relative abundances (peak area) of two ion transitions and reten-
tion times were compared in order to verify the absence of
interferences for both diagnostic ions.
2.6.1 | Precision
Three sets of 10 replicates of blank urine samples were spiked with
standard working solution at three different concentrations, low
1 ng/ml, medium 10 ng/ml, and high 50 ng/ml (n = 3  10) and were
analyzed. Coefficient of variation (CV) of areas (normalized with IS)
for intra- and inter-day precision for three concentration levels was
calculated by measuring samples on three consecutive days.
2.6.2 | Robustness
Blank urine samples with various specific gravities (0.005, 0.010,
0.020, 0.025, and 0.030) and different pH values (3, 4.5, 6, 7.5, and 9)
were spiked with 1-ng/ml standard working solution and were
analyzed. Additionally, increasing injection volumes (15, 20, 25, 30,
and 35 μl) were tested (n = 15). Comparison of retention times and
relative abundances of two ion transitions was carried out.
TABLE 1 Mass transitions used for
parallel reaction monitoring (PRM) for
17-epistanozolol-10N- and
17-epistanozolol-20N-glucuronide (e1N-
SG and e2N-SG) and IS d3-testosterone-
glucuronide (D3-TG)
Substance Formula Precursor ion Species Product ion 1 Product ion 2
(m/z) (m/z)/(eV) (m/z)/(eV)
e1N-SG C27H40N2O7 505.2908 [M + H]+ 329.2587/60 81.0447/70
e2N-SG C27H40N2O7 505.2908 [M + H]+ 329.2587/60 81.0447/70
D3-TG C25H32D3O8 468.2671 [M + H]+ 109.0645/35 97.0651/35
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2.6.3 | Linearity
Calibration curves were generated by measuring four replicates of
urine samples spiked with standard working solution at six different
concentrations (1, 10, 25, 50, 75, and 100 ng/ml, n = 4  6). The
Software Thermo Quan Browser was used to calculate linearity (R2).
2.6.4 | Accuracy
Three sets of 10 replicates of blank urine samples were spiked with
standard working solution at three different concentrations, low
1 ng/ml, medium 10 ng/ml, and high 50 ng/ml (n = 3  10) and
were measured. Accuracy (determined concentration/nominal con-
centration*100%) was calculated.
2.6.5 | Matrix effects
Six different blank urine samples and one matrix-free sample
(MQ) were spiked with 1-ng/ml standard working solution and mea-
sured. Average matrix effects (ion suppression or enhancement)
were calculated by comparing signal area (normalized with IS) of
urine samples to the matrix-free sample.
2.6.6 | Carryover
Blank urine sample was spiked with 400-ng/ml standard working
solution and measured directly prior to a blank urine sample. The
intensity of signal area (normalized with IS) in the blank sample was
calculated (%).
2.6.7 | Limit of identification
Three sets of three different blank urine samples were spiked with
standard working solution at three concentrations (0.05, 0.075, and
0.1 ng/ml, n = 3  3), close to an estimated LOI and were analyzed.
According to WADA specifications, LOI was defined as the lowest
concentration level at which the analytical signal meets the regula-
tions for relative abundance and retention times. The acronym LOI,
used by WADA, is coequal with the more known term limit of
detection (LOD).
3 | RESULTS AND DISCUSSION
3.1 | Method validation
The method validation parameters of the 17-epistanozolol-
N-glucuronides are quite similar to the values observed for
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determined validation parameter values for 17-epistanozolol-10N- and
17-epistanozolol-20N-glucuronide are summarized.
Passing the WADA identification criteria in 10 of 10 samples for
both metabolites reflects this method's high specificity. No interfering
signals could be observed. Furthermore, suitable intra- (CV 1.9%–
4.8%) and inter-day (CV 2.7%–7.4%) precision values and satisfying
accuracy parameters (90.6%–102.1%) were achieved. R2 values (0.999
and 0.997) confirm a linear signal response development with increas-
ing substance concentration for both metabolites. Suitable robustness
in 15 of 15 samples was accomplished for the 17-epistanozolol-20N
metabolite. However, for the 17-epistanozolol-10N metabolite, only
14 of 15 samples passed the identification criteria. The sample with
an injection volume of 35 μl could not pass the criteria. In this sample,
product ion 2 (m/z 81) showed a disproportionately increased abun-
dance compared to product ion 1 (m/z 329), leading to a bigger area
ratio than a reference sample without matrix and with smaller injec-
tion volume. No carryover effect at all was observed after injection of
a high concentration sample. Probably due to the lack of comprehen-
sive sample preparation, high matrix effects (177% and 184%) were
observed, which, however, do not seem to have a negative influence
on precision and accuracy of the method. Nevertheless, for pure
quantitative measurements a matching deuterated IS is rec-
ommended. Fulfilling WADAs identification criteria, we could detect
both 17-epistanozolol-10N-glucuronide and 17-epistanozolol-20N-
glucuronide at the lowest concentration of 100 pg/ml. By applying
alternative criteria for the calculation of the LOI, for example, a signal/
noise ratio of >3, the LOIs would be even lower (50 pg/ml). These
suitable validation parameters promise a reliable use of this method
for the confirmation of stanozolol doping in routine anti-doping
analysis.
3.2 | Identification of 17-epistanozolol-N-
glucuronides
In order to identify the two metabolites in question, 17-epistanozolol-
10N- and 17-epistanozolol-20N-glucuronide, HRMS/MS measure-
ments were performed with the above-described PRM method on
stanozolol positive urine samples, blank urine samples, and urine sam-
ples spiked with reference standards. Extracted ion chromatograms
(XIC) with the transition m/z = 505.2908 à 329.2578 are shown in
Figure 3-I.
F IGURE 3 Results of parallel reaction
monitoring (PRM) measurements; I: XIC of
positive urine, blank urine and reference
standards; m/z 505.2908 à 329.2587
(60 eV), ESI+, 5-ppm mass tolerance II:
Corresponding PRM spectra of
17-epistanozolol-10N- (a, c) and
17-epistanozolol-20N-glucuronide (b, d)
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The analysis of a number of positive urine samples showed that
17-epistanozolol-20N-glucuronide (B) is excreted only in significantly
lower concentrations, mostly below the detection limit of this
method, compared to 17-epistanozolol-10N-glucuronide (A). In the
positive sample shown as an example in this paper, it was possible
to provide evidence for the appearance of 17-epistanozolol-20N-
glucuronide (B). In order to visualize the corresponding peak, the
chromatogram was expanded at the relevant position. In the blank
sample, no signals have been observed. The urine sample spiked
with reference standards (2.5 ng/ml) shows excellent signals for
both 17-epistanozolol-10N-glucuronide (C) and 17-epistanozolol-
20N-glucuronide (D). In Figure 3-II, the corresponding PRM mass
spectra are shown. All four signals exhibit a highly similar mass
spectrometric pattern. Both metabolites form the two stanozolol-
glucuronide specific product ions at m/z 329 and 81. The product
ion at m/z 329 is formed by the cleavage of the glucuronic acid
and represents the resulting stanozolol aglycone molecule. The
product ion at m/z 81 is suggested to consist of a robust
heterocyclic pyridazine hexagonal ring structure. It is formed by
fusing the pyrazole ring with an additional C atom from the
sterane backbone during the fragmentation process.13 In all four
cases, the deviation of the theoretical mass from the experimental
mass was less than 5 ppm for the ion at m/z 329. For the ion
at m/z 81, the mass deviation is below 7 ppm, explainable by
the higher amount of interfering signals in the area of smaller
masses.
Comparing retention times and at least two MS/MS transitions
of the targeted analyte in a positive sample and a reference sample
is required to fulfill WADA identification criteria. The relative
abundance of diagnostic ions can be determined from peak areas or
heights. In this work, peak areas were used. Table 3 shows the com-
parative calculations of retention times and abundances, as well as
the criteria to be met.
With 0.2% difference for 17-epistanozolol-10N-glucuronide and
0.1% for 17-epistanozolol-20N-glucuronide, for both metabolites,
the relative differences of retention times were significantly below
the maximum tolerance of 1%. Furthermore, the relative area abun-
dances' differences were 0.6% and 0.8%, which is also far below the
tolerated 5% aberrance. These data provide the unequivocal
proof of the existence of 17-epistanozolol-10N-glucuronide and
17-epistanozolol-20N-glucuronide in human urine after ingestion of
the exogenous steroid stanozolol.
3.3 | Excretion study
W. Schänzer et al. demonstrated the utility of stanozolol-
glucuronides to improve the detection of stanozolol abuse by ana-
lyzing excretion study samples in their work in 2013 for the first
time.19 In the following years, further research teams confirmed
the usefulness of these metabolites for long-term detection
of stanozolol administration in their studies with a higher
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of stanozolol.15,16 However, due to the lack of proper reference sub-
stances, in all cases, metabolite elimination data were presented based
on relative signal intensities rather than metabolite concentrations.
The re-analysis of the same excretion samples used in the work of
W. Schänzer provided similar if not equal results including substance
concentrations as shown in Figure 4. However, this study focuses only
on the analysis of stanozolol-N-glucuronides. The chart shows the
concentrations of the four different N-glucuronide metabolites in
human urine over time in hours. In order to ensure better
comparability of concentrations, values were adjusted for the urine
specific gravity according to WADA recommendations and are
presented on a logarithmic scale.34
These data clearly confirm the large excretion window of
17-epistanozolol-10N-glucuronide, which is up to almost 4 weeks.
Compared to all other known stanozolol metabolites, this metabolite
has the largest timeframe for detection.29 Stanozolol-10N-glucuronide
was detectable up to 12 days. The two 20N-glucuronides show shorter
detection windows up to only 2 days. A major difference in the con-
centrations of the metabolites can also be observed. At the maximum,
stanozolol-10N-glucuronide is excreted in about 25 times higher con-
centration compared to 17-epistanozolol-10N-glucuronide. As already
mentioned above, 17-epistanozolol-20N-glucuronide is only excreted
in comparably low concentrations, which is clearly demonstrated in
these samples. Almost all data points for this metabolite are below the
LOI of the method. Consequently, the concentrations of
17-epistanozolol-20N-glucuronide below the LOI of 0.1 ng/ml,
presented in Figure 4, do not meet the WADA criteria and shall be
interpreted as indicative. This metabolite is regarded as of minor
importance for the long-term detection of stanozolol doping, but may
nevertheless provide information about the time of application of
stanozolol, if successfully detected.
4 | CONCLUSION
With the previously developed fully automated SPE-LC-HRMS
method, a simple and fast procedure yielding excellent validation
parameters for the analysis of 17-epistanozolol-N-glucuronides has
been established. Using this method, the presence of
17-epistanozolol-10N-glucuronide and 17-epistanozolol-20N-
glucuronide in human urine after intake of stanozolol was unequivo-
cally confirmed. Furthermore, due to access to high-quality reference
samples, an elimination curve based on the absolute metabolite con-
centrations of all four stanozolol-N-glucuronides in human urine
excretion samples was shown for the first time. The long detection
window of up to almost 28 days, the ease of analysis, and the access
to synthesized reference standards qualify these metabolites as
suitable targets for routine stanozolol analysis.
The fact that these N-glucuronides, some of which exhibit
very large detection windows, are resistant to β-glucuronidase
means that the long detection time frames of stanozolol are not
fully utilized today, because normal ITP relies on the use of
β-glucuronidase.
Furthermore, the direct analysis of glucuronide metabolites
delivers promising results for many other substances, too.
Therefore, consideration should be given to complementing the
usual ITP with an approach involving the direct analysis of glucuro-
nide metabolites of doping substances without the use of
glucuronidase.
Direct analysis of steroid phase-II metabolites is deemed to bring
many advantages to the field of anti-doping analysis. Therefore, the
characterization of new unknown metabolites and the subsequent
production of reference substances should stay in focus of current
research.
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